Antiparkinsonian Anticholinergic Agents

Antiparkinsonian anticholinergic agents are a therapeutic class of centrally active muscarinic receptor antagonists—such as trihexyphenidyl and benztropine—designed to restore neurochemical equilibrium within the basal ganglia They function by competitively inhibiting muscarinic acetylcholine receptors, thereby counteracting the relative cholinergic excess that occurs following the loss of striatal dopamine

Antiparkinsonian anticholinergic agents are a therapeutic class of centrally active muscarinic receptor antagonists—such as trihexyphenidyl and benztropine—designed to restore neurochemical equilibrium within the basal ganglia

Antiparkinsonian anticholinergic agents are a therapeutic class of centrally active muscarinic receptor antagonists—such as trihexyphenidyl and benztropine—designed to restore neurochemical equilibrium within the basal ganglia

They function by competitively inhibiting muscarinic acetylcholine receptors, thereby counteracting the relative cholinergic excess that occurs following the loss of striatal dopamine

Clinically, these medications are primarily utilized as adjunctive or monotherapy in idiopathic Parkinson disease—most notably to alleviate resting tremor and rigidity—as well as to manage medication-induced extrapyramidal symptoms and acute dystonic reactions associated with antipsychotic and dopamine-blocking therapies

Clinically, these medications are primarily utilized as adjunctive or monotherapy in idiopathic Parkinson disease—most notably to alleviate resting tremor and rigidity—as well as to manage medication-induced extrapyramidal symptoms and acute dystonic reactions associated with antipsychotic and dopamine-blocking therapies